Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96P66
UPID:
GP101_HUMAN
Alternative names:
-
Alternative UPACC:
Q96P66; Q5JSM8; Q8NG93
Background:
The Probable G-protein coupled receptor 101, identified by the accession number Q96P66, plays a pivotal role as an orphan receptor. Its precise biological functions are yet to be fully elucidated, making it a subject of significant scientific interest.
Therapeutic significance:
Linked to Pituitary adenoma 2, a growth hormone-secreting benign neoplasm, this protein's aberrations are implicated in acromegaly and gigantism. Understanding the role of Probable G-protein coupled receptor 101 could open doors to potential therapeutic strategies for these conditions.